Lifeward

Company Overview

Snapshot

Founded in June 2001, Lifeward operates with 11–50 employees and has raised a total of $249.72 million across 20 funding rounds from 11 investors. The company went public on NASDAQ in September 2014, marking a significant milestone in its journey.

Business overview

Lifeward is a Health Tech & Life Sciences company focused on developing groundbreaking solutions for individuals with physical limitations or disabilities. The company's core technology revolves around wearable robotic exoskeletons for walking, serving the rehabilitation, orthopedics, and assistive devices markets. Its product portfolio includes the ReWalk Exoskeleton, ReStore Exo-Suit.

Strategic signal

In November 2023, Medicare proposed a preliminary reimbursement level for the ReWalk Personal Exoskeleton, a historic move that signals a significant step towards broader accessibility and coverage for advanced assistive devices. This development is crucial for Lifeward as it could substantially increase market penetration and adoption of its personal exoskeleton systems, validating the company's long-term strategy for regulatory and reimbursement pathways.

Company Intelligence Q&A

What was a significant recent development regarding Medicare coverage for Lifeward's products?

In November 2023, Medicare proposed a preliminary reimbursement level for the ReWalk Personal Exoskeleton, marking a historic step towards facilitating access to the device.

When did Lifeward go public and on which exchange?

Lifeward went public on NASDAQ in September 2014, raising $36 million in its Initial Public Offering.

What was a key acquisition made by Lifeward?

In August 2023, Lifeward acquired AlterG, a move aimed at enhancing its product portfolio and driving profitability.

What was a notable product milestone achieved by the company in 2018?

In November 2018, ReWalk announced the placement of its 500th exoskeleton system, demonstrating significant adoption of its technology.

What was a significant regulatory achievement for ReWalk's ReBoot Soft Exo-Suit?

In November 2021, the FDA designated ReWalk's ReBoot Soft Exo-Suit as a Breakthrough Device, recognizing its potential to provide more effective treatment for life-threatening or irreversibly debilitating diseases or conditions.